Targovax ASA said its pancreatic cancer drug TG01 delivered encouraging survival outcomes in a phase 1/2 study.

The trial enrolled 32 patients with surgically removed adenocarcinoma of the pancreas, treated with TG01 and chemotherapy.

Data showed patients survived a median of 16.1 months without their cancer worsening — a measure called median disease-free survival, or mDFS. Median overall survival was 33.4 months, with 72% of patients alive at the two-year mark.

Targovax said 19 patients received up to 36 injections of TG01 mostly before and during gemcitabine chemotherapy, while 13 patients received up to 15 injections of TG01 mostly after gemcitabine chemotherapy — the optimized dosing regimen.

Patients on the optimized dosing regimen had a 19.5-month mDFS, compared to 13.9 months in the other patient group.

Full data from the trial will be presented Oct. 15 at the Targovax capital markets update.

TG01 is Targovax's lead product candidate from its mutant RAS neoantigen cancer vaccine program. The Oslo-based immuno-oncology company reported positive clinical study data on TG01 in June 2017.